Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Can Regenerative Medicine be the Cure for Cancer and Other Deadly Diseases?

Published: Thursday, June 19, 2014
Last Updated: Thursday, June 19, 2014
Bookmark and Share
Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products.

Regenerative medicine has the potential to transform healthcare all over the world and usher human health into a new era of wellness. Currently, the majority of treatments for chronic and fatal diseases is palliative or to delay disease progression; in contrast, regenerative medicine is uniquely capable of altering the underlying disease mechanism and enabling cures.

New analysis from Frost & Sullivan’s Global Regenerative Medicine Market finds the increasing approval rates and clinical activity buzz point to regenerative medicine being an extremely attractive sector for investors. It covers the segments of cell therapy (CT), tissue engineering (TE), gene therapy (GT) and small molecules and biologics.

"Cell-based models are anticipated to speed-up the discovery of new molecules and biologics, the safety and toxicity testing of newly discovered drugs, and provide a solid understanding of underlying disease mechanisms,” said Frost & Sullivan Healthcare Senior Research Analyst Aiswariya Chidambaram. "As more pharma companies acquire profitable cell therapy companies or strategically invest in emerging cell and advanced therapy organizations, the consolidation wave is likely to rise higher in the industry."

A significant number of regenerative medicine products, particularly in CT and TE, are already commercially available. In 2012, the market witnessed the approval of as many as seven CT products by regulatory agencies worldwide, while only five such approvals were granted between 2009 and 2011, and none from 2002 to 2008.

However, despite the immense value of regenerative medicine, there is a lack of consensus and strategic interaction among members of the regenerative medicine community. There has to be greater assessment of activities at various federal agencies including government, industry, academia, and patient advocates, particularly in the U.S., to identify areas of redundancy and eventually bridge the gap.

To set up a more efficient coverage and a solid reimbursement framework, the various stakeholders have to streamline regulatory policies. They could achieve this by establishing a clear point of contact at the national level that will act as an interface among the Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), National Institutes of Health (NIH), National Center for Health Statistics (NCHS), other federal agencies and the private sector.

They will also do well to create fora/platforms to present recommendations for regulatory, reimbursement and research policies in order to foster product and clinical development.

"On the whole, governments all over the world are expected to implement legislative policies favouring the establishment of centres of excellence, manufacturing infrastructure, research networks and economic diversification to support the development of regenerative medicine," noted Chidambaram.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Increased Public Private Partnerships to Drive Cutting Edge Innovation and Business Growth
Faced with increasing challenges such as costly treatments and treatments that are palliative rather than symptomatic, the global healthcare industry today is gradually transforming itself.
Thursday, October 08, 2015
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Monday, August 24, 2015
Changing Phase of Biomarkers
Discover the current scenario and changing business models of the biomarkers field.
Monday, April 13, 2015
Companion Diagnostics Benefit from Fewer Regulatory Barriers in Europe
Future revisions to in-vitro diagnostics laws will offset the launch of new tests, in a market expected to soar to $1,295.1 million in 2018.
Thursday, June 26, 2014
Gene Expression Profiling Drives Personalized Medicine Worldwide
Large amounts of information generated by gene expression profiling will increase implementation of data management tools.
Tuesday, June 10, 2014
Personalized Medicine Drives Uptake of Next-generation Sequencing in Europe
Future of DNA sequencing will shift from a laboratory-based setup to point of care testing in the next 5 years.
Saturday, May 31, 2014
Emerging Technologies Redefine Infectious Disease Diagnostics
The largest opportunities lie in the developing regions of Asia, Africa and Latin America.
Wednesday, April 23, 2014
Drug Developers Drawn to Orphan Drugs Market
Breakthrough therapies for rare diseases command premium pricing, particularly if no alternatives exist.
Thursday, March 27, 2014
Next-Generation Therapeutics for Infectious Diseases Conquer the Global Spotlight
Resistance to current drugs spurs treatment innovation in influenza, respiratory syncytial virus, chlamydia and gonorrhea.
Thursday, March 27, 2014
Live Cell Imaging Revolutionizes Disease Diagnostics and Drug Discovery
Stakeholder collaboration will be crucial to convert these developments into clinically meaningful tests.
Friday, March 21, 2014
Automated Anatomic Pathology Labs Transform Global Tissue Diagnostics Market
Offering attractive procurement strategies will boost adoption of high-end tools.
Thursday, February 06, 2014
Strong Pipeline of mAbs Biosimilars in the US and Europe Lends Impetus to Global Market
The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019.
Tuesday, February 04, 2014
Predictions for the Global Chemicals, Materials and Food Industry
New insights based on Frost & Sullivan's ‘2013 Search for Growth’ survey.
Wednesday, December 11, 2013
CMOs Can Reduce Vendor Switching with Informational Marketing Efforts
Frost & Sullivan: Companies opt for CMOs offering high-quality services, confidentiality and clean regulatory track records.
Tuesday, November 26, 2013
Next Generation Sequencing Bioinformatics Heats up: Nearing $1000 Genome Sparks Soaring Data Output
Frost & Sullivan: Healthcare innovation hinges on managing escalating amounts of data priming to more than triple the market.
Wednesday, November 13, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos